Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes

International Journal of Sports Medicine

Volumn 24, Issue 4, 2003, Pages 252-257

  Varlet Marie, E ^a   Gaudard, A ^a   Audran, M ^a   Gomeni, R ^a,b   Bressolle, F ^a  

^a UNIV MONTPELLIER   (France)

^b GSK   (Italy)

Author keywords

Erythropoietin abuse; Indirect detection; Negative feedback loop; Repeated subcutaneous administrations

Indexed keywords

FERROUS SULFATE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HORMONE; TRANSFERRIN RECEPTOR;

ARTICLE; ATHLETE; CLINICAL ARTICLE; DISEASE MARKER; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; NEGATIVE FEEDBACK; RETICULOCYTE; RETICULOCYTOSIS;

ADULT; BLOOD PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEEDBACK, BIOCHEMICAL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MODELS, BIOLOGICAL; RECEPTORS, TRANSFERRIN; RETICULOCYTE COUNT; SPORTS;

EID: 0038807904     PISSN: 01724622     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39506     Document Type: Article

References (31)

1. Annable L, Cotes PM, Musset MV. The Second International Reference Preparation of Epo, human, urinary, for bioassay. Bull Wld Hlth Org 1972; 47: 99-112
2. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart MT, Marion B, Bressolle F. Indirect detection of erythropoietin abuse in doping control. Med Sci Sports Exerc 1999; 31: 639-653
3. Beal SL, Sheiner LB. NONMEM User's Guide, University of California at San Francisco, San Francisco, USA
4. Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy males. J Intern Med 1991; 229: 125-130
5. Birkeland K, Hemmersbach P. Issues related to blood sampling in athletes for doping control. Sports Med 1999; 28: 25-30
6. Bressolle F, Audran M, Gareau R, Baynes RD, Guidicelli C, Gomeni R. Population pharmacodynamics for monitoring of recombinant human erythropoietin: a new approach in doping control. Clin Drug Invest 1997; 14: 233-242
7. Casoni I, Ricci G, Ballarin E, Borseto C, Grazzi G, Guglielmini C, Manfredi F, Mazzoni G, Patracchini M, de Paoli Vitali E, Rigolin F, Bartalotta S, Franzè GP, Masotti M, Conconi F. Haematological indices of erythropoietin administration in athletes. Int J Sports Med 1993; 14: 307-311
8. Cotes PM, Brozovic B. Diurnal variation of serum immunoreactive erythropoietin in a normal subject. Clin Endocrinol 1982; 17: 419-422
9. Eckardt KU, Kurtz A, Hirth P, Scigalla P, Wieczorek L, Bauer C. Evaluation of the stability of human erythropoietin in samples for radioimmunoassay. Kiln Wschr 1988; 66: 241-245
10. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. Scand J Med Sci Sports 1991; 1: 88-93
11. Fuseau E, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35: 733-741
12. Gareau R, Gagnon MG, Ayotte C, Chenard C, Brisson GR. rHuEpo increases urinary excretion of fibrin degradation products in haemodialysis patients. Thromb Haemost 1993; 70: 373-374
13. Gareau R, Gagnon MG, Thellend C, Chenard C, Audran M, Chanal JL, Ayotte C, Brisson GR. Transferrin soluble receptor: a possible probe for detection of erythropoietin abuse by athletes. Horm Metab Res 1994; 26: 311-312
14. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA. Comparative pharmacokinetics and pharmacodynamics of epoetin alpha and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-712
15. Jensen JD, Jensen LW, Madsen JK, Poulsen L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 995; 54: 111-116
16. Jelkman W. Biology of erythropoietin. Clin Invest 1994; 72: S3-S10
17. Kicman AT, Cowan DA. Peptides hormones and sport: misuse and detection. Br Med Bull 1992; 48: 496-517
18. Klausen T, Dela F, Hippe E, Galbo H. Diurnal variations of serum erythropoietin in trained and untrained subjects. Eur J Appl Physiol 1993; 67: 545-548
19. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649-663
20. Magnani M, Corsi D, Blanchi M, Palardini M, Galluzzi L, Parisi A, Pigozzi F. Monitoring erythropoietin abuse in athletes. Br J Haematol 1999; 106: 260-261
21. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Peery B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. Blood 1990; 76: 1718-1722
22. Miller ME, Garcia JF, Cohen RA, Cronkite EP, Moccia G, Jacevedo R. Diurnal levels of immunoreactive erythropoietin in normal subjects and subjects with chronic lung disease. Br J Haematol 1981; 49: 189-200
23. Parisotto R, Gore CJ, Emslie KR, Asheden MJ, Brugnara C, Howe C, Martin T, Trout GT, Hahn AG. A novel method utilizing markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000; 85: 564-572
24. Parisotto R, Moutian W, Asheden MJ, Emslie KR, Gore CJ, Howe, C. Kazlauskas R, Sharpe K, Trout GJ, Xie M, Hahn AG. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001; 86: 128-137
25. Parisotto R., Gore CJ, Hahn AG, Asheden MJ, Olds TS, Martin DT, Pyne DB, Gawthorn K, Brugnara C. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. Int J Sports Med 2000; 21: 471-479
26. Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990; 29: 709-713
27. Sawka MN, Joyner MJ, Miles DS, Robertson RJ, Spriet LL, Young AJ. The use of blood doping as an ergogenic aid. Med Sci Sports Exerc 1996; 28: I-VIII
28. Schwandt HJ, Heyduck B, Genga HC, Rocker L. Influence of prolonged physical exercise on the erythropoietin concentration in blood. Eur J Appl Physiol 1991; 63: 463-466
29. Schmidt W, Eckardt KU, Hilgendorf A, Strauch S, Bauer C. Effect of maximal and submaximal exercise under normoxic and hypoxic conditions on serum erythropoietin level. Int J Sports Med 1991; 12: 457-461
30. Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol 1996; 42: 355-360
31. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the linear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 1995; 84: 760-767